TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02664064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prevent
Description: Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
Study: NCT02076347

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Office visit intervention
Description: Pharmacist communicates monitoring recommendations to physician through the electronic medical record prior to a scheduled patient office visit

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Message Intervention
Description: Pharmacist communicates need for monitoring directly to patients and instructs them to obtain monitoring on their own time without need for an office visit with physician
Study: NCT02961387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen generator treatment
Description: The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Hydrogen generator treatment
Description: The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen-making machine treatment
Description: The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Oxygen-making machine treatment
Description: The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.
Study: NCT03364036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mavenclad®
Description: Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
Study: NCT05240703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stabilization splint treatment
Description: The stabilization splints were made of heat-cured acrylic by the same dental technician. The occlusion of the splint was defined in the centric relation occlusion using wax (Astynax, Associated Dental Products Ltd, UK). The patients were instructed to use the splint every night during the course of the study. The patients were instructed to perform a standardized program for masticatory muscle exercises. At the beginning of the training program, active mouth openings, laterotrusive movements and protrusive movements were performed. The mandible was held in the maximal positions for a few seconds on each movement. Thereafter, these movements were made towards resistance (using the patient's own fingers). After jaw exercises, the patients were suggested to open the jaw wide, stretching it with fingers a few times for 10 to 20 seconds. These movements were repeated 7 to 10 times per training session, and the sessions were performed 2-3 times per day.
Study: NCT01859949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotropin (somatropin)
Description: Genotropin(somatoropin) 12 mg, Genotropin(somatropin) will be given at a dose of 0.067 mg/kg/day or 0.033 mg/kg/day to all participating patients
Study: NCT01153009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Description: Encapsulated vortioxetine immediate release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Overencapsulated duloxetine delayed-release capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching capsules
Study: NCT03960827

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RE Training
Description: Participants randomized to RE engage in four center-based RE sessions each week for 12 weeks; each session lasting roughly 1-hour with a 40-45 minute stimulus phase and the remaining time being used to warm up and cool down. The prescription is a 2-day split, meaning approximately half of the major muscle groups are exercised each session and each muscle group is exercised twice per week. Two sessions per week include seven exercises that focus on the hips/thighs, back and biceps, and the other two sessions per week include seven exercises that focus on the chest, shoulders, triceps, calves and abdominal muscles. The first set per muscle group is a warm-up performed at 50-70% of prescribed loads that are based on 10-repetition maximum (10RM). Three sets per exercise are then performed at 10RM intensity. Load increases when a participant can perform 12 repetitions for 2 of 3 sets of an exercise. During all sessions, heart rate is monitored and perceived exertion is recorded.
Study: NCT03992378

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Level Transcutaneous Vagus Nerve Stimulation
Description: Stimulation of the auricular branch of the vagus nerve at tragus of the external ear delivered by Parasym device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Low Level Transcutaneous Vagus Nerve Stimulation
Description: Stimulation of the ear lobe delivered by Parasym device.
Study: NCT01909960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow imaging
Description: Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in Larson's score and MMSE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flow imaging
Description: Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.~Clinical examination consists in Larson's score and MMSE
Study: NCT01305772

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Panitumumab
Description: Single dose Panitumumab 9mg/kg IV (in the vein) prior to definitive therapy (surgery or radiation therapy). Two additional doses of panitumumab 9mg/kg IV may be given at weeks 1 \& 4 of RT alone or weeks 1 \& 4 of cisplatin/RT if they tolerated first dose of panitumumab.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Single dose Panitumumab 9mg/kg IV (in the vein) prior to definitive therapy (surgery or radiation therapy). Two additional doses of panitumumab 9mg/kg IV may be given at weeks 1 \& 4 of RT alone or weeks 1 \& 4 of cisplatin/RT if they tolerated first dose of panitumumab.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Second biopsy was taken from surgical resection tissue (when possible obtained pre and post panitumumab biopsies from the same site).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Radiation therapy was initiated within 8 weeks after surgery, or as soon as possible.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy was initiated within 8 weeks after surgery, or as soon as possible.
Study: NCT04557436

Intervention type: DRUG
Group type: OTHER
Intervention: PBLTT52CAR19
Description: gene therapy
Study: NCT05645861

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure management of Systolic Blood Pressure to maintain target range +/- 10 mmHg
Description: Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood pressure management of Systolic Blood Pressure to maintain target range +/- 10 mmHg
Description: Techniques used to target SBP will not be controlled for and will be at the discretion of the procedural anaesthetist to manage blood pressure, this can include vasopressors, intravenous fluids, titration of anaesthetic maintenance drugs and use of other vasoactive drugs.
Study: NCT01115387

Intervention type: OTHER
Intervention: Observational-1
Description: Multiple questionnaires detailing family history, medical history, visual symptoms, smoking, environmental and dietary exposures.~Prospective photography of the retina to detect early ARM-related changes A saliva or blood sample for genetic testing.

Intervention type: OTHER
Intervention: Observational-1
Description: Multiple questionnaires detailing family history, medical history, visual symptoms, smoking, environmental and dietary exposures.~Prospective photography of the retina to detect early ARM-related changes A saliva or blood sample for genetic testing.

Intervention type: OTHER
Intervention: Observational-2
Description: A limited number of questionnaires and prior clinical documentation from eye care professionals of eye status with respect to ARM.~No prospective retina photographs but ongoing follow-up for reported changes in ARM status.~A saliva or blood sample for genetic testing.
Study: NCT00858806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib
Description: Intermittent Imatinib administration.~* 1 week on / 1 week off for the 1st month(weeks 1-4)~* 2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~* 1 month on / 1 month off from the 4th month thereafter (weeks 13 on)
Study: NCT00645372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Description: Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6
Study: NCT03373747

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Reliability of IET
Description: The participants will be do three sessions: familiarization, test and retest to assess the reliability inter and intra rater of the test.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Physiological analysis of IET
Description: The participants will be submitted two sessions, familiarization session and test session. In the test session there will be the physiological analysis by means of gas analysis, blood lactate concentrate and activation muscular percentage.
Study: NCT02804048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: superficial heat pelvic floor muscle
Description: Superficial heat application in the pelvic floor muscle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: superficial heat low back
Description: Superficial heat application in the low back

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: Pelvic floor muscle training exercises

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Manual therapy in iliopsoas, diaphragm and piriformis
Description: Manual therapy in iliopsoas, diaphragm and piriformis for 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy in iliopsoas, diaphragm and piriformis
Description: Manual therapy in iliopsoas, diaphragm and piriformis for 10 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra Vaginal Manual therapy
Description: Intra Vaginal Manual therapy in the pelvic floor muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Description: Electromyographic biofeedback in the pelvic floor muscles
Study: NCT00546169

Intervention type: DRUG
Intervention: Fibrinogen (human) + thrombin (human) (TachoSil)
Description: haemorrhages in cholecystectomy
Study: NCT01156493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein Hydrolyzed Premature Formula
Description: Infants will be fed with a protein hydrolyzed premature formula until they reach full feeds
Study: NCT02143024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based depression intervention
Description: The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care plus educational materials
Description: Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.
Study: NCT01614444

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Acupressure Treatment
Description: Participant will receive 8 active acupressure treatments.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupressure Treatment
Description: Participants will receive 8 placebo acupressure treatments.
Study: NCT02861430

Intervention type: PROCEDURE
Intervention: Immunochemistry and molecular biology on sentinel lymph node specimen
Study: NCT02991963

Intervention type: OTHER
Intervention: Interview
Description: A survey will be included patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones

Intervention type: OTHER
Intervention: Interview
Description: A survey will be included patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones

Intervention type: OTHER
Intervention: Blood collection (Dried Blood Spot)
Description: Dried Blood Spot

Intervention type: OTHER
Intervention: Blood Collection (Venous Blood collection)
Description: Venous Blood collection

Intervention type: OTHER
Intervention: Blood Collection (Venous Blood collection)
Description: Venous Blood collection

Intervention type: OTHER
Intervention: Blood Smear
Description: Slide blood smear

Intervention type: OTHER
Intervention: Blood Smear
Description: Slide blood smear
Study: NCT03208894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: efficacy of salbutamol and furosemide in TTN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: efficacy of salbutamol and furosemide in TTN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection
Description: efficacy of salbutamol and furosemide in TTN
Study: NCT00813878

Intervention type: GENETIC
Intervention: protein analysis
Description: protein analysis

Intervention type: GENETIC
Intervention: protein analysis
Description: protein analysis

Intervention type: GENETIC
Intervention: protein expression analysis
Description: protein expression analysis

Intervention type: GENETIC
Intervention: protein expression analysis
Description: protein expression analysis

Intervention type: GENETIC
Intervention: proteomic profiling
Description: proteomic profiling

Intervention type: GENETIC
Intervention: proteomic profiling
Description: proteomic profiling

Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Description: Performed one time on study

Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Description: Performed one time on study

Intervention type: OTHER
Intervention: immunohistochemistry staining method
Description: Performed one time on study

Intervention type: OTHER
Intervention: immunohistochemistry staining method
Description: Performed one time on study

Intervention type: OTHER
Intervention: liquid chromatography
Description: Performed on samples collected one time on study

Intervention type: OTHER
Intervention: liquid chromatography
Description: Performed on samples collected one time on study

Intervention type: OTHER
Intervention: mass spectrometry
Description: Performed on samples collected one time on study

Intervention type: OTHER
Intervention: mass spectrometry
Description: Performed on samples collected one time on study

Intervention type: PROCEDURE
Intervention: fine-needle aspiration
Description: Samples collected one time on study at the appointment for fine-needle aspiration where applicable

Intervention type: PROCEDURE
Intervention: fine-needle aspiration
Description: Samples collected one time on study at the appointment for fine-needle aspiration where applicable

Intervention type: PROCEDURE
Intervention: needle biopsy
Description: Samples collected one time on study at the appointment for needle biopsy where applicable

Intervention type: PROCEDURE
Intervention: needle biopsy
Description: Samples collected one time on study at the appointment for needle biopsy where applicable

Intervention type: PROCEDURE
Intervention: radiomammography
Description: Samples collected one time on study at the appointment for radiomammography where applicable

Intervention type: PROCEDURE
Intervention: radiomammography
Description: Samples collected one time on study at the appointment for radiomammography where applicable
Study: NCT00314808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol
Description: Oral route, 5mg PO 2x daily before and during 2 cycles of chemotherapy,2.5mg PO every night when not on chemotherapy
Study: NCT00964379

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraperitoneal or extraperitoneal colostomy
Description: creation of colostomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraperitoneal or extraperitoneal colostomy
Description: creation of colostomy
Study: NCT03103256

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHP1701
Description: PO, Once daily (QD), 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YHR1703
Description: PO, Once daily (QD), 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: YHR1704
Description: PO, Once daily (QD), 8 weeks
Study: NCT02667314

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jigsaw puzzles
Description: Intervention period 1: Participants are asked to solve jigsaw puzzles at home 6 times per week for at least 1 hour over a period of 5 weeks.~Intervention period 2 (voluntary): Participants receive the possibility to solve jigsaw puzzles free-of-charge at home for a period of at least 3 month before the 1.5-year follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive health counseling
Description: Cognitive health counseling regarding modifiable risk and protective factors of cognitive decline and dementia at baseline, and four telephone calls for expert monitoring (three calls during the 5-week period between pre- and posttest, and one call 12 month later)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive health counseling
Description: Cognitive health counseling regarding modifiable risk and protective factors of cognitive decline and dementia at baseline, and four telephone calls for expert monitoring (three calls during the 5-week period between pre- and posttest, and one call 12 month later)
Study: NCT03271593

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT01790802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2RT nanosecond laser
Description: active laser therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 2RT nanosecond laser
Description: active laser therapy
Study: NCT03207490

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMADEO
Description: Robot therapy: 1-Degrees-Of-Freedom (1DOFs) robot training for flexion and extention movements of the hand.~Standard rehabilitation therapy includes speech, physical, occupational therapies and group activities
Study: NCT00667914

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: geriatric work-up
Description: Pre- and postoperative treatment of hip-fracture patients in an orthogeriatric unit(geriatric evaluation and management)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orthopedic care as usual
Description: treatment in ordinary orthopedic unit
Study: NCT03058718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procalcitonin
Description: The application of antimicrobial agents is determined by PCT results.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Experience
Description: The application of antimicrobial agents is determined by clinical experience of doctors.
Study: NCT03923777

Intervention type: OTHER
Group type: OTHER
Intervention: Active Surveillance
Description: Agreeing to postpone treatment while continuing with a CT scan surveillance regimen to follow tumor growth. SABR should be offered if either the tumor is \>3 cm in size or the VDT decreases to \<400 days.
Study: NCT01317498

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: CD4, liver function and CBC every 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virological Monitoring
Description: Viral Load test every 6 months
Study: NCT03758768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue light exposure
Description: Light administered through ceiling mounted light emitting diode (LED)-based room lighting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full spectrum light exposure
Description: Light administered through ceiling mounted light emitting diode (LED)-based room lighting.
Study: NCT02393131

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hippocampal avoidance WBRT
Description: Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conformal WBRT
Description: Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
Study: NCT00405015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: Rosiglitazone 4 mg bidaily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: Rosiglitazone 4 mg bidaily for 8 weeks